Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Quality Assurance: SOP for Internal Quality Audits in Injectable Manufacturing – V 2.0

Posted on By

Quality Assurance: SOP for Internal Quality Audits in Injectable Manufacturing – V 2.0

Standard Operating Procedure for Internal Quality Audits in Injectable Manufacturing


Department Quality Assurance
SOP No. SOP/QA/181/2025
Supersedes SOP/QA/181/2022
Page No. Page 1 of 13
Issue Date 24/06/2025
Effective Date 26/06/2025
Review Date 24/06/2026

1. Purpose

To define the standard procedure for planning, conducting, reporting, and following up on internal quality audits in the sterile injectable manufacturing facility. The objective is to verify compliance with GMP, internal procedures, and regulatory requirements, ensuring continuous improvement of quality

systems.

2. Scope

This SOP applies to all departments involved in sterile injectable manufacturing including production, quality control, engineering, warehouse, validation, and documentation functions. It encompasses routine, focused, and follow-up audits.

3. Responsibilities

  • Audit Coordinator (QA): Plans and schedules audits, assigns auditors, ensures report compilation and closure of audit observations.
  • Auditors: Conduct audits objectively and document findings.
  • Auditees: Provide access to information, cooperate with auditors, and implement corrective actions.
  • Department Heads: Review and respond to audit findings, ensure closure of non-conformities.
See also  Sterile Injection Manufacturing: SOP for Handling Packing Line Discrepancies - V 2.0

4. Accountability

The Head of Quality Assurance is accountable for ensuring that internal audits are conducted as per the approved schedule and that non-conformances are resolved in a timely and effective manner.

5. Procedure

5.1 Preparation of Audit Schedule

  1. The Audit Coordinator shall prepare an annual internal audit schedule (Annexure-1) at the beginning of the calendar year based on risk assessment and past audit findings.
  2. The schedule shall be reviewed and approved by the Head QA and communicated to all departments.

5.2 Selection and Training of Auditors

  1. Auditors shall be selected from QA and trained in auditing principles, GMP guidelines, and applicable regulatory standards.
  2. They must be independent of the areas being audited.

5.3 Conducting the Audit

  1. Auditors shall:
    • Refer to the checklist (Annexure-2) for each department/process.
    • Review documents, observe activities, and interview personnel.
    • Record all observations, including non-conformities (NC), observations (OBS), and suggestions (SUG).

5.4 Classification of Findings

  1. Non-conformities shall be categorized as:
    • Critical: Impacting product quality or patient safety.
    • Major: Deviation from SOPs, GMP, or documentation norms.
    • Minor: Low-risk procedural or documentation lapses.
See also  Quality Control: SOP for Handling Out-of-Specification (OOS) Results in QC - V 2.0

5.5 Reporting

  1. Audit Report (Annexure-3) shall be prepared within 5 working days of the audit and submitted to the auditee department and QA Head.
  2. It shall include summary, classification, and suggested corrective actions.

5.6 Corrective and Preventive Actions (CAPA)

  1. Auditee departments must submit CAPA plans (Annexure-4) within 10 working days.
  2. CAPAs must include root cause analysis, corrective measures, and preventive steps.

5.7 Follow-Up and Closure

  1. QA shall verify implementation of CAPAs through:
    • Review of records
    • Follow-up audits if necessary
  2. Closure of each audit shall be recorded in the Audit Closure Log (Annexure-5).

5.8 Documentation and Retention

  1. All audit-related documents shall be retained for a minimum of 5 years.
  2. They must be available for external audits and inspections.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • NC: Non-Conformance
  • CAPA: Corrective and Preventive Action
  • GMP: Good Manufacturing Practice

7. Documents

  1. Internal Audit Schedule – Annexure-1
  2. Audit Checklist – Annexure-2
  3. Audit Report – Annexure-3
  4. CAPA Form – Annexure-4
  5. Audit Closure Log – Annexure-5
See also  Sterile Injectable Manufacturing: SOP for Compatibility Studies of Container Closure Systems - V 2.0

8. References

  • WHO TRS 986 Annex 2 – GMP for Sterile Pharmaceutical Products
  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211 – cGMP Regulations

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation QA Executive QA Manager Head QA
Department Quality Assurance Quality Assurance Quality Assurance

11. Annexures

Annexure-1: Internal Audit Schedule

Department Scheduled Date Auditor(s)
Production 15/01/2025 Sunita Reddy
QC 20/01/2025 Rajesh Kumar

Annexure-2: Audit Checklist

Area Audit Point Compliant (Y/N) Remarks
Documentation Batch records updated in real-time Y

Annexure-3: Audit Report

Date Department Auditor Findings Classification
15/01/2025 Production Sunita Reddy Missing calibration record Major

Annexure-4: CAPA Form

Finding Root Cause Corrective Action Preventive Action Responsible
Missing calibration Oversight Recalibrated equipment Monthly log audit Rajesh Kumar

Annexure-5: Audit Closure Log

Audit Date Department Closure Date Verified By
15/01/2025 Production 25/01/2025 QA Manager

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial release New SOP QA Head
24/06/2025 2.0 Updated checklist and annexures Periodic Review QA Head
Injectables V 2.0 Tags:Aseptic processing SOP, Aseptic technique in sterile manufacturing, Cleanroom SOP for injectables, SOP for ampoule sealing, SOP for autoclave sterilization, SOP for container closure integrity testing, SOP for environmental monitoring in aseptic area, SOP for gowning in cleanroom, SOP for in-process checks in sterile manufacturing, SOP for injectable formulation, SOP for lyophilizer operation, SOP for sterile filtration, SOP for sterilization validation, SOP for vial filling, SOP for visual inspection of injectables, Sterile area cleaning SOP, Sterile filling line SOP, Sterile injectable quality control SOP, Sterile injection SOP, Sterile manufacturing procedure

Post navigation

Previous Post: Audit Case Studies on Inadequate SOP Training
Next Post: Gel Manufacturing: SOP for Ensuring Batch-to-Batch Consistency in Gels – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version